Detecting ultra-rare analytes for infectious disease and beyond
MEET ACCELEVIRDX
WHO WE ARE
Accelevir Diagnostics is a Maryland biotechnology company developing innovative assays for ultra-rare analytes in infectious disease and beyond. Our team brings expertise in virology, immunology, and assay commercialization.
OUR APPROACH
We employ advanced ddPCR, qPCR, and sequencing as well as culture-based approaches to develop scalable assays for difficult to detect pathogens that can support the continuum from basic research through clinical trials. We are currently focused on advancing new assays for persistent HIV-1 and other clinically important viral infections.
COLLABORATIONS AND FUNDING
To date, we have received over $5M in federal, state and private funding to advance our assays. We are actively working with leading academic and bio-pharma groups to provide our assays in support of translational research and early-stage clinical trials.
RECENT NEWS
AND PUBLICATIONS
February 2020
AccelevirDx announces joint publication with Deeks lab at UCSF describing differential dynamics of intact and defective HIV-1 proviruses in people on ART (JCI Insight, 2020, PMID 32045386)
NIH
January 2019
AccelevirDx is announces receipt of NIH SBIR Phase I funding to support SIV/SHIV ddPCR assay development
!
December 2019
AccelevirDx is excited to announce our move to expanded laboratories at Columbus Center! We are thrilled to join a wonderful group of exciting biotech companies in Baltimore's Inner Harbor.
NSF
September 2019
AccelevirDx announces receipt of NSF Phase IIB funding to support expanded ddPCR assay development and sequencing
February 2019
AccelevirDx announces joint publication with Siliciano lab at Johns Hopkins describing novel HIV assay (Nature, 2019, PMID 30700913)
NSF
September 2018
AccelevirDx announces receipt of NSF TECP funding to support expanded HIV ddPCR assay development
NIH
September 2018
AccelevirDx announces receipt of NIH SBIR Phase I funding to support development of tissue assays for latent HIV
NIH
January 2018
AccelevirDx announces receipt of NIH SBIR Phase II funding to support development of novel molecular latent HIV